Barry Uretsky
Concepts (599)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Percutaneous Coronary Intervention | 97 | 2024 | 299 | 23.450 |
Why?
| Coronary Occlusion | 58 | 2023 | 78 | 13.600 |
Why?
| Coronary Artery Disease | 40 | 2024 | 274 | 13.340 |
Why?
| Fractional Flow Reserve, Myocardial | 39 | 2023 | 126 | 12.150 |
Why?
| Angioplasty, Balloon, Coronary | 48 | 2020 | 130 | 11.240 |
Why?
| Stents | 50 | 2023 | 338 | 8.830 |
Why?
| Coronary Angiography | 95 | 2023 | 336 | 8.510 |
Why?
| Coronary Vessels | 32 | 2024 | 152 | 8.010 |
Why?
| Coronary Stenosis | 22 | 2021 | 99 | 6.600 |
Why?
| Myocardial Infarction | 46 | 2024 | 382 | 5.350 |
Why?
| Drug-Eluting Stents | 22 | 2023 | 93 | 5.220 |
Why?
| Treatment Outcome | 119 | 2024 | 5138 | 4.860 |
Why?
| Cardiac Catheterization | 19 | 2023 | 196 | 4.230 |
Why?
| Coronary Artery Bypass | 17 | 2022 | 120 | 3.080 |
Why?
| Acute Coronary Syndrome | 8 | 2022 | 78 | 3.030 |
Why?
| Humans | 222 | 2024 | 49827 | 2.770 |
Why?
| Chronic Disease | 52 | 2023 | 563 | 2.520 |
Why?
| Tomography, Optical Coherence | 8 | 2018 | 95 | 2.480 |
Why?
| Saphenous Vein | 12 | 2021 | 65 | 2.270 |
Why?
| Graft Occlusion, Vascular | 13 | 2021 | 74 | 2.240 |
Why?
| Platelet Aggregation Inhibitors | 11 | 2014 | 174 | 2.180 |
Why?
| Risk Factors | 63 | 2023 | 3619 | 2.170 |
Why?
| Coronary Thrombosis | 8 | 2020 | 23 | 2.050 |
Why?
| Registries | 32 | 2023 | 518 | 1.910 |
Why?
| Myocardial Ischemia | 11 | 2020 | 120 | 1.860 |
Why?
| Male | 116 | 2024 | 25093 | 1.840 |
Why?
| Cardiology | 13 | 2019 | 89 | 1.810 |
Why?
| Coronary Restenosis | 8 | 2021 | 31 | 1.790 |
Why?
| Thrombosis | 11 | 2018 | 249 | 1.780 |
Why?
| Predictive Value of Tests | 22 | 2023 | 904 | 1.770 |
Why?
| Myocardium | 17 | 2013 | 429 | 1.700 |
Why?
| Aged | 68 | 2023 | 9272 | 1.650 |
Why?
| Heptanoic Acids | 15 | 2008 | 34 | 1.620 |
Why?
| Pyrroles | 15 | 2008 | 69 | 1.580 |
Why?
| Time Factors | 39 | 2023 | 2912 | 1.550 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 13 | 2022 | 138 | 1.500 |
Why?
| Middle Aged | 75 | 2024 | 11997 | 1.460 |
Why?
| Heart Injuries | 3 | 2019 | 15 | 1.440 |
Why?
| Risk Assessment | 26 | 2023 | 1262 | 1.410 |
Why?
| Myocardial Reperfusion Injury | 10 | 2011 | 48 | 1.290 |
Why?
| Cardiac Tamponade | 2 | 2024 | 26 | 1.240 |
Why?
| Female | 77 | 2024 | 26329 | 1.200 |
Why?
| Collateral Circulation | 10 | 2020 | 39 | 1.200 |
Why?
| Vasodilator Agents | 5 | 2016 | 97 | 1.100 |
Why?
| Coronary Circulation | 9 | 2024 | 57 | 1.090 |
Why?
| Heart-Assist Devices | 3 | 2020 | 147 | 1.070 |
Why?
| Prosthesis Design | 11 | 2021 | 236 | 1.010 |
Why?
| Contrast Media | 8 | 2018 | 183 | 1.010 |
Why?
| Cardiac Catheters | 4 | 2020 | 12 | 1.010 |
Why?
| Societies, Medical | 9 | 2019 | 175 | 1.010 |
Why?
| Thrombolytic Therapy | 2 | 2020 | 111 | 0.990 |
Why?
| Ventricular Dysfunction, Left | 6 | 2018 | 92 | 0.980 |
Why?
| Heart Failure | 11 | 2019 | 454 | 0.980 |
Why?
| Pericarditis | 2 | 2022 | 20 | 0.960 |
Why?
| Ventricular Function, Left | 11 | 2023 | 154 | 0.930 |
Why?
| Adenosine | 7 | 2018 | 69 | 0.930 |
Why?
| Balloon Occlusion | 1 | 2024 | 18 | 0.920 |
Why?
| Pericardial Effusion | 1 | 2024 | 42 | 0.900 |
Why?
| Hemorrhage | 4 | 2019 | 202 | 0.890 |
Why?
| Cardiovascular Agents | 5 | 2009 | 54 | 0.880 |
Why?
| Coronary Disease | 5 | 2015 | 132 | 0.880 |
Why?
| Occupational Health | 1 | 2023 | 67 | 0.860 |
Why?
| Aneurysm, False | 5 | 2020 | 44 | 0.860 |
Why?
| Postoperative Complications | 9 | 2019 | 1000 | 0.850 |
Why?
| Pericarditis, Constrictive | 1 | 2022 | 3 | 0.850 |
Why?
| Aorta | 3 | 2019 | 160 | 0.810 |
Why?
| Hypotension, Controlled | 1 | 2021 | 3 | 0.800 |
Why?
| Radiography, Interventional | 7 | 2018 | 60 | 0.790 |
Why?
| Retrospective Studies | 27 | 2020 | 6117 | 0.790 |
Why?
| Anemia | 1 | 2022 | 68 | 0.790 |
Why?
| Thrombocytopenia | 1 | 2022 | 84 | 0.770 |
Why?
| Mammary Arteries | 3 | 2017 | 8 | 0.760 |
Why?
| Absorbable Implants | 2 | 2022 | 16 | 0.760 |
Why?
| Inferior Wall Myocardial Infarction | 1 | 2020 | 1 | 0.740 |
Why?
| Time-to-Treatment | 2 | 2020 | 62 | 0.730 |
Why?
| Thiazolidinediones | 6 | 2008 | 82 | 0.730 |
Why?
| Shock, Cardiogenic | 1 | 2020 | 25 | 0.710 |
Why?
| Algorithms | 4 | 2021 | 616 | 0.710 |
Why?
| Prognosis | 16 | 2023 | 1952 | 0.710 |
Why?
| Cardiovascular Diseases | 11 | 2015 | 440 | 0.700 |
Why?
| Digitalis | 1 | 2019 | 4 | 0.690 |
Why?
| Diabetic Angiopathies | 2 | 2013 | 18 | 0.690 |
Why?
| Enbucrilate | 1 | 2019 | 6 | 0.690 |
Why?
| Tissue Adhesives | 1 | 2019 | 14 | 0.680 |
Why?
| Arterial Pressure | 1 | 2019 | 45 | 0.680 |
Why?
| Hyperemia | 3 | 2016 | 19 | 0.680 |
Why?
| Pericardium | 4 | 2022 | 29 | 0.680 |
Why?
| Guideline Adherence | 1 | 2020 | 132 | 0.660 |
Why?
| Operative Time | 3 | 2019 | 75 | 0.660 |
Why?
| Practice Guidelines as Topic | 2 | 2020 | 448 | 0.640 |
Why?
| Aspirin | 5 | 2022 | 114 | 0.630 |
Why?
| Hematoma | 2 | 2013 | 66 | 0.630 |
Why?
| Hydrostatic Pressure | 1 | 2017 | 8 | 0.600 |
Why?
| Follow-Up Studies | 16 | 2019 | 2179 | 0.600 |
Why?
| Angioplasty, Balloon | 4 | 2022 | 65 | 0.590 |
Why?
| Death, Sudden, Cardiac | 2 | 2008 | 53 | 0.590 |
Why?
| Heart Septum | 2 | 2010 | 23 | 0.590 |
Why?
| Perioperative Care | 5 | 2015 | 42 | 0.590 |
Why?
| Creatine Kinase, MB Form | 3 | 2013 | 6 | 0.590 |
Why?
| Adrenergic beta-Antagonists | 3 | 2008 | 102 | 0.580 |
Why?
| Foramen Ovale, Patent | 2 | 2014 | 27 | 0.570 |
Why?
| Surgical Procedures, Operative | 4 | 2015 | 69 | 0.560 |
Why?
| Purinergic P2Y Receptor Antagonists | 2 | 2014 | 29 | 0.550 |
Why?
| Heart Ventricles | 4 | 2012 | 248 | 0.540 |
Why?
| Veterans | 1 | 2022 | 550 | 0.530 |
Why?
| Severity of Illness Index | 13 | 2019 | 942 | 0.530 |
Why?
| Propranolol | 2 | 2008 | 78 | 0.530 |
Why?
| Prospective Studies | 14 | 2023 | 2344 | 0.520 |
Why?
| Alloys | 2 | 2020 | 9 | 0.520 |
Why?
| United States | 24 | 2022 | 4838 | 0.520 |
Why?
| Electrocardiography | 9 | 2022 | 253 | 0.520 |
Why?
| Aortic Valve | 3 | 2022 | 113 | 0.500 |
Why?
| Fibrinolytic Agents | 3 | 2014 | 125 | 0.500 |
Why?
| Vascular System Injuries | 1 | 2015 | 36 | 0.490 |
Why?
| Tomography, X-Ray Computed | 5 | 2013 | 1159 | 0.490 |
Why?
| Wounds, Penetrating | 1 | 2015 | 43 | 0.490 |
Why?
| Randomized Controlled Trials as Topic | 9 | 2015 | 553 | 0.480 |
Why?
| Stroke Volume | 7 | 2023 | 115 | 0.480 |
Why?
| Ultrasonography, Interventional | 7 | 2013 | 135 | 0.480 |
Why?
| Cardiotonic Agents | 7 | 2019 | 66 | 0.470 |
Why?
| Purines | 2 | 2014 | 38 | 0.470 |
Why?
| Adenosine A2 Receptor Agonists | 1 | 2014 | 5 | 0.470 |
Why?
| Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2009 | 32 | 0.470 |
Why?
| Physician-Patient Relations | 1 | 2015 | 140 | 0.460 |
Why?
| Anterior Wall Myocardial Infarction | 2 | 2012 | 7 | 0.460 |
Why?
| Metals | 2 | 2011 | 34 | 0.460 |
Why?
| Computer-Assisted Instruction | 1 | 2014 | 31 | 0.460 |
Why?
| Cyclooxygenase 2 | 8 | 2008 | 45 | 0.460 |
Why?
| Piperazines | 2 | 2012 | 117 | 0.450 |
Why?
| Blood Vessel Prosthesis Implantation | 4 | 2009 | 119 | 0.450 |
Why?
| Pyrazoles | 2 | 2014 | 113 | 0.450 |
Why?
| Anticholesteremic Agents | 3 | 2008 | 28 | 0.450 |
Why?
| Troponin T | 2 | 2011 | 12 | 0.450 |
Why?
| Mentors | 1 | 2014 | 55 | 0.450 |
Why?
| Atrial Function, Left | 1 | 2013 | 3 | 0.450 |
Why?
| Arteries | 1 | 2013 | 94 | 0.440 |
Why?
| Incidence | 12 | 2018 | 1003 | 0.440 |
Why?
| Endarterectomy, Carotid | 2 | 2011 | 62 | 0.440 |
Why?
| Lipoxins | 3 | 2008 | 3 | 0.440 |
Why?
| Cardiac Surgical Procedures | 3 | 2014 | 298 | 0.430 |
Why?
| Tissue Donors | 1 | 2013 | 111 | 0.430 |
Why?
| Drug Eruptions | 1 | 2012 | 13 | 0.420 |
Why?
| Rats, Sprague-Dawley | 14 | 2008 | 1595 | 0.420 |
Why?
| Thiophenes | 1 | 2012 | 36 | 0.410 |
Why?
| Physicians | 2 | 2015 | 234 | 0.410 |
Why?
| Rats | 19 | 2011 | 3300 | 0.410 |
Why?
| Stroke | 3 | 2013 | 492 | 0.400 |
Why?
| Drug Administration Schedule | 5 | 2014 | 376 | 0.400 |
Why?
| Embolism | 2 | 2013 | 20 | 0.400 |
Why?
| Cyclooxygenase Inhibitors | 5 | 2007 | 39 | 0.400 |
Why?
| Quality Assurance, Health Care | 4 | 2012 | 149 | 0.400 |
Why?
| Diverticulum | 1 | 2011 | 22 | 0.390 |
Why?
| Internet | 1 | 2014 | 261 | 0.390 |
Why?
| Troponin I | 1 | 2011 | 18 | 0.380 |
Why?
| Transurethral Resection of Prostate | 1 | 2011 | 10 | 0.380 |
Why?
| Carotid Arteries | 1 | 2011 | 85 | 0.380 |
Why?
| Intraoperative Complications | 4 | 2020 | 119 | 0.380 |
Why?
| Pressure | 3 | 2017 | 102 | 0.380 |
Why?
| Clinical Trials as Topic | 4 | 2012 | 460 | 0.380 |
Why?
| Receptors, Adrenergic, beta-2 | 2 | 2009 | 16 | 0.380 |
Why?
| Myocytes, Cardiac | 5 | 2011 | 125 | 0.380 |
Why?
| Embolic Protection Devices | 1 | 2010 | 6 | 0.380 |
Why?
| Paclitaxel | 1 | 2011 | 84 | 0.370 |
Why?
| Receptors, Opioid, delta | 2 | 2009 | 26 | 0.370 |
Why?
| Clinical Competence | 4 | 2013 | 398 | 0.370 |
Why?
| Heart | 5 | 2006 | 326 | 0.360 |
Why?
| Pericardiectomy | 2 | 2024 | 6 | 0.360 |
Why?
| Mitral Valve | 1 | 2010 | 49 | 0.360 |
Why?
| Endocarditis | 1 | 2010 | 32 | 0.360 |
Why?
| Kaplan-Meier Estimate | 6 | 2017 | 469 | 0.350 |
Why?
| Sirolimus | 2 | 2009 | 62 | 0.340 |
Why?
| Hypoglycemic Agents | 3 | 2006 | 166 | 0.330 |
Why?
| Anticoagulants | 5 | 2024 | 254 | 0.330 |
Why?
| Echocardiography, Transesophageal | 2 | 2006 | 60 | 0.330 |
Why?
| Carotid Artery, Common | 2 | 2006 | 44 | 0.320 |
Why?
| Myocardial Bridging | 1 | 2008 | 2 | 0.320 |
Why?
| Heart Failure, Systolic | 1 | 2008 | 7 | 0.320 |
Why?
| Tissue Plasminogen Activator | 1 | 2009 | 110 | 0.320 |
Why?
| Peptides | 2 | 2008 | 222 | 0.320 |
Why?
| Suction | 1 | 2008 | 23 | 0.310 |
Why?
| Aortic Valve Stenosis | 2 | 2022 | 60 | 0.310 |
Why?
| Consensus | 2 | 2007 | 143 | 0.310 |
Why?
| Azetidines | 1 | 2008 | 6 | 0.310 |
Why?
| Heart Valve Prosthesis | 2 | 2022 | 75 | 0.310 |
Why?
| Patient Selection | 7 | 2012 | 251 | 0.310 |
Why?
| Telemedicine | 1 | 2014 | 443 | 0.300 |
Why?
| Heart Septal Defects, Atrial | 2 | 2013 | 44 | 0.300 |
Why?
| Vascular Patency | 5 | 2020 | 83 | 0.290 |
Why?
| Laboratories, Hospital | 1 | 2006 | 6 | 0.280 |
Why?
| Coronary Aneurysm | 1 | 2007 | 17 | 0.280 |
Why?
| Defibrillators, Implantable | 2 | 2007 | 58 | 0.280 |
Why?
| Terminology as Topic | 3 | 2013 | 63 | 0.280 |
Why?
| Echocardiography, Three-Dimensional | 1 | 2006 | 12 | 0.280 |
Why?
| Pacemaker, Artificial | 1 | 2007 | 33 | 0.280 |
Why?
| Animals | 25 | 2022 | 13150 | 0.280 |
Why?
| Chi-Square Distribution | 3 | 2017 | 282 | 0.280 |
Why?
| Mitral Valve Insufficiency | 2 | 2007 | 44 | 0.280 |
Why?
| Hemodynamics | 6 | 2018 | 229 | 0.270 |
Why?
| Angina, Unstable | 3 | 2016 | 17 | 0.270 |
Why?
| Bacteremia | 1 | 2007 | 92 | 0.260 |
Why?
| Inpatients | 2 | 2018 | 189 | 0.260 |
Why?
| Gadolinium DTPA | 1 | 2005 | 25 | 0.260 |
Why?
| Kidney Failure, Chronic | 2 | 2004 | 197 | 0.260 |
Why?
| Lipopolysaccharides | 1 | 2006 | 191 | 0.260 |
Why?
| Nitric Oxide Synthase Type III | 6 | 2008 | 78 | 0.260 |
Why?
| Carotid Artery Diseases | 1 | 2005 | 33 | 0.260 |
Why?
| Neovascularization, Physiologic | 2 | 2005 | 67 | 0.250 |
Why?
| Angina, Stable | 2 | 2016 | 7 | 0.250 |
Why?
| Prostaglandins | 1 | 2005 | 20 | 0.250 |
Why?
| Pain Management | 3 | 2015 | 146 | 0.250 |
Why?
| Calcium | 1 | 2007 | 397 | 0.250 |
Why?
| Program Evaluation | 1 | 2006 | 349 | 0.250 |
Why?
| Renal Insufficiency | 1 | 2005 | 109 | 0.250 |
Why?
| Chemokine CCL2 | 1 | 2004 | 71 | 0.240 |
Why?
| Plasminogen Activator Inhibitor 1 | 1 | 2004 | 6 | 0.240 |
Why?
| Europe | 6 | 2019 | 74 | 0.240 |
Why?
| History, 21st Century | 2 | 2019 | 57 | 0.240 |
Why?
| Pericardiocentesis | 1 | 2024 | 16 | 0.240 |
Why?
| Monocytes | 1 | 2004 | 132 | 0.230 |
Why?
| Equipment Design | 3 | 2020 | 282 | 0.230 |
Why?
| History, 20th Century | 2 | 2019 | 100 | 0.230 |
Why?
| Secondary Prevention | 2 | 2015 | 78 | 0.230 |
Why?
| Proportional Hazards Models | 4 | 2017 | 406 | 0.230 |
Why?
| Reoperation | 5 | 2013 | 452 | 0.230 |
Why?
| Heart Rupture, Post-Infarction | 1 | 2003 | 2 | 0.230 |
Why?
| Staphylococcal Infections | 1 | 2007 | 269 | 0.230 |
Why?
| Reproducibility of Results | 6 | 2016 | 1188 | 0.230 |
Why?
| Cardiomyopathy, Hypertrophic | 1 | 2004 | 31 | 0.230 |
Why?
| Nitric Oxide Synthase Type II | 4 | 2008 | 66 | 0.220 |
Why?
| Digoxin | 2 | 2019 | 21 | 0.220 |
Why?
| Double-Blind Method | 5 | 2020 | 674 | 0.220 |
Why?
| Disease Models, Animal | 9 | 2011 | 1451 | 0.220 |
Why?
| Calcinosis | 1 | 2023 | 49 | 0.220 |
Why?
| Materials Testing | 2 | 2020 | 58 | 0.210 |
Why?
| American Heart Association | 4 | 2015 | 32 | 0.210 |
Why?
| Hospital Mortality | 5 | 2019 | 413 | 0.210 |
Why?
| Dose-Response Relationship, Drug | 8 | 2017 | 1374 | 0.210 |
Why?
| Adult | 11 | 2019 | 13160 | 0.210 |
Why?
| Femoral Artery | 2 | 2019 | 100 | 0.210 |
Why?
| Coronary Vessel Anomalies | 2 | 2017 | 37 | 0.200 |
Why?
| Recurrence | 6 | 2016 | 651 | 0.200 |
Why?
| Angiography | 3 | 2012 | 126 | 0.190 |
Why?
| Retreatment | 2 | 2012 | 58 | 0.190 |
Why?
| Drug Therapy, Combination | 5 | 2008 | 378 | 0.190 |
Why?
| Heart Valve Prosthesis Implantation | 2 | 2016 | 80 | 0.190 |
Why?
| Vasodilation | 1 | 2021 | 97 | 0.190 |
Why?
| Up-Regulation | 4 | 2011 | 450 | 0.180 |
Why?
| United States Department of Veterans Affairs | 1 | 2022 | 279 | 0.180 |
Why?
| Ischemia | 1 | 2021 | 152 | 0.180 |
Why?
| Angioplasty | 1 | 2020 | 20 | 0.180 |
Why?
| Calcitonin Gene-Related Peptide | 2 | 2009 | 22 | 0.170 |
Why?
| 6-Ketoprostaglandin F1 alpha | 3 | 2008 | 6 | 0.170 |
Why?
| Plaque, Atherosclerotic | 1 | 2019 | 38 | 0.170 |
Why?
| Logistic Models | 3 | 2018 | 891 | 0.170 |
Why?
| Specialization | 1 | 2019 | 46 | 0.170 |
Why?
| Atherectomy | 1 | 2019 | 13 | 0.170 |
Why?
| Russia | 4 | 2019 | 10 | 0.160 |
Why?
| Cost-Benefit Analysis | 2 | 2014 | 273 | 0.160 |
Why?
| Propanolamines | 2 | 2011 | 14 | 0.160 |
Why?
| Quality Improvement | 2 | 2011 | 212 | 0.160 |
Why?
| Radial Artery | 1 | 2019 | 31 | 0.160 |
Why?
| Peripheral Arterial Disease | 1 | 2019 | 67 | 0.160 |
Why?
| Catheterization | 1 | 2019 | 97 | 0.160 |
Why?
| Proto-Oncogene Proteins c-akt | 3 | 2009 | 157 | 0.160 |
Why?
| Odds Ratio | 3 | 2016 | 548 | 0.160 |
Why?
| Catheterization, Peripheral | 1 | 2019 | 47 | 0.160 |
Why?
| Patient Care Planning | 1 | 2019 | 67 | 0.160 |
Why?
| Aged, 80 and over | 5 | 2017 | 3125 | 0.160 |
Why?
| Feasibility Studies | 1 | 2020 | 374 | 0.160 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2004 | 467 | 0.150 |
Why?
| Emergency Medical Services | 1 | 2019 | 111 | 0.150 |
Why?
| Patient Safety | 1 | 2018 | 101 | 0.150 |
Why?
| Medicare | 2 | 2011 | 244 | 0.150 |
Why?
| Education, Medical | 1 | 2019 | 112 | 0.150 |
Why?
| Constriction, Pathologic | 1 | 2017 | 94 | 0.150 |
Why?
| Adventitia | 1 | 2017 | 4 | 0.150 |
Why?
| Hospitalization | 3 | 2011 | 653 | 0.150 |
Why?
| Education, Medical, Graduate | 3 | 2013 | 208 | 0.150 |
Why?
| Curriculum | 3 | 2013 | 404 | 0.140 |
Why?
| Cardiac Pacing, Artificial | 2 | 2008 | 28 | 0.140 |
Why?
| Risk | 2 | 2011 | 320 | 0.140 |
Why?
| Prevalence | 4 | 2018 | 943 | 0.140 |
Why?
| Advisory Committees | 2 | 2014 | 63 | 0.140 |
Why?
| Survival Analysis | 3 | 2010 | 659 | 0.140 |
Why?
| Nitric Oxide Synthase | 2 | 2008 | 75 | 0.140 |
Why?
| Phosphorylation | 6 | 2008 | 536 | 0.140 |
Why?
| Propensity Score | 1 | 2017 | 124 | 0.140 |
Why?
| Simvastatin | 2 | 2008 | 29 | 0.140 |
Why?
| Aortic Valve Insufficiency | 1 | 2016 | 21 | 0.130 |
Why?
| Administration, Oral | 5 | 2015 | 423 | 0.130 |
Why?
| Benzazepines | 2 | 2006 | 19 | 0.130 |
Why?
| Renal Insufficiency, Chronic | 1 | 2018 | 168 | 0.130 |
Why?
| Postpericardiotomy Syndrome | 1 | 2015 | 4 | 0.130 |
Why?
| Diagnostic Techniques, Cardiovascular | 2 | 2012 | 4 | 0.130 |
Why?
| Magnetic Resonance Imaging | 1 | 2022 | 1533 | 0.130 |
Why?
| Angina Pectoris | 2 | 2020 | 18 | 0.120 |
Why?
| Colchicine | 1 | 2015 | 28 | 0.120 |
Why?
| Smad3 Protein | 1 | 2014 | 9 | 0.120 |
Why?
| Th2 Cells | 1 | 2014 | 21 | 0.120 |
Why?
| Cholesterol, Dietary | 1 | 2014 | 19 | 0.120 |
Why?
| Cyclic AMP-Dependent Protein Kinases | 3 | 2011 | 51 | 0.120 |
Why?
| Patient Care Management | 1 | 2014 | 18 | 0.120 |
Why?
| Area Under Curve | 3 | 2022 | 181 | 0.120 |
Why?
| Venous Thrombosis | 1 | 2015 | 91 | 0.120 |
Why?
| Receptors, LDL | 1 | 2014 | 66 | 0.120 |
Why?
| Cardiovascular System | 1 | 2014 | 49 | 0.120 |
Why?
| Atherosclerosis | 2 | 2014 | 214 | 0.120 |
Why?
| Thromboembolism | 1 | 2014 | 54 | 0.120 |
Why?
| Dependovirus | 1 | 2014 | 101 | 0.110 |
Why?
| Remote Consultation | 1 | 2014 | 29 | 0.110 |
Why?
| Transfection | 1 | 2014 | 357 | 0.110 |
Why?
| Drug Costs | 1 | 2014 | 39 | 0.110 |
Why?
| Quality Indicators, Health Care | 2 | 2011 | 86 | 0.110 |
Why?
| Arrhythmias, Cardiac | 2 | 2012 | 93 | 0.110 |
Why?
| Septal Occluder Device | 1 | 2013 | 26 | 0.110 |
Why?
| Echocardiography, Doppler, Color | 1 | 2013 | 23 | 0.110 |
Why?
| Pulmonary Edema | 1 | 2013 | 19 | 0.110 |
Why?
| Echocardiography, Doppler | 2 | 2016 | 52 | 0.110 |
Why?
| Cohort Studies | 5 | 2022 | 1422 | 0.110 |
Why?
| Signal Transduction | 3 | 2009 | 1617 | 0.110 |
Why?
| Heparin | 2 | 2024 | 92 | 0.110 |
Why?
| Evidence-Based Medicine | 2 | 2011 | 248 | 0.110 |
Why?
| General Surgery | 1 | 2014 | 109 | 0.110 |
Why?
| Pleural Effusion | 1 | 2013 | 38 | 0.110 |
Why?
| Case-Control Studies | 2 | 2013 | 1128 | 0.110 |
Why?
| Kidney Diseases | 2 | 2007 | 214 | 0.100 |
Why?
| Image Processing, Computer-Assisted | 1 | 2014 | 241 | 0.100 |
Why?
| Myocardial Revascularization | 2 | 2012 | 13 | 0.100 |
Why?
| Embolism, Cholesterol | 1 | 2011 | 2 | 0.100 |
Why?
| Hypertrophy, Left Ventricular | 2 | 2009 | 34 | 0.100 |
Why?
| Age Factors | 3 | 2021 | 1090 | 0.100 |
Why?
| Cardiovascular Surgical Procedures | 2 | 2012 | 10 | 0.100 |
Why?
| Ultrasonography | 2 | 2010 | 436 | 0.100 |
Why?
| Milrinone | 1 | 2011 | 9 | 0.100 |
Why?
| Treatment Failure | 2 | 2018 | 113 | 0.100 |
Why?
| Insurance Claim Review | 1 | 2011 | 36 | 0.100 |
Why?
| Enkephalin, D-Penicillamine (2,5)- | 2 | 2009 | 3 | 0.100 |
Why?
| Unnecessary Procedures | 1 | 2011 | 21 | 0.090 |
Why?
| Equipment Failure | 2 | 2008 | 62 | 0.090 |
Why?
| Punctures | 2 | 2019 | 47 | 0.090 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 66 | 0.090 |
Why?
| Multivariate Analysis | 3 | 2016 | 585 | 0.090 |
Why?
| Thrombectomy | 1 | 2011 | 66 | 0.090 |
Why?
| Cyclooxygenase 2 Inhibitors | 2 | 2007 | 19 | 0.090 |
Why?
| Injections, Intra-Arterial | 2 | 2015 | 13 | 0.090 |
Why?
| Necrosis | 1 | 2010 | 177 | 0.090 |
Why?
| Surgical Instruments | 1 | 2010 | 28 | 0.090 |
Why?
| Magnetic Resonance Imaging, Cine | 1 | 2010 | 56 | 0.090 |
Why?
| Disease Management | 3 | 2014 | 174 | 0.090 |
Why?
| Systole | 1 | 2010 | 68 | 0.090 |
Why?
| Reperfusion Injury | 2 | 2007 | 87 | 0.090 |
Why?
| Receptors, Calcitonin Gene-Related Peptide | 1 | 2009 | 4 | 0.090 |
Why?
| Phosphodiesterase Inhibitors | 2 | 2007 | 23 | 0.090 |
Why?
| Myocardial Contraction | 2 | 2009 | 105 | 0.080 |
Why?
| Cells, Cultured | 3 | 2009 | 1571 | 0.080 |
Why?
| ROC Curve | 2 | 2022 | 232 | 0.080 |
Why?
| Hyperlipidemias | 2 | 2011 | 49 | 0.080 |
Why?
| Endothelium, Vascular | 2 | 2007 | 254 | 0.080 |
Why?
| Drug Administration Routes | 1 | 2008 | 10 | 0.080 |
Why?
| Leukotriene B4 | 1 | 2008 | 1 | 0.080 |
Why?
| Arachidonate 5-Lipoxygenase | 1 | 2008 | 4 | 0.080 |
Why?
| Hemostasis, Surgical | 1 | 2008 | 12 | 0.080 |
Why?
| Fatal Outcome | 2 | 2007 | 195 | 0.080 |
Why?
| Survival Rate | 3 | 2018 | 905 | 0.080 |
Why?
| Phospholipases A | 2 | 2006 | 13 | 0.080 |
Why?
| Phospholipases A2 | 2 | 2006 | 14 | 0.080 |
Why?
| Patient Transfer | 1 | 2009 | 95 | 0.080 |
Why?
| Comorbidity | 1 | 2010 | 618 | 0.080 |
Why?
| Diabetes Complications | 2 | 2011 | 118 | 0.080 |
Why?
| Meta-Analysis as Topic | 1 | 2008 | 40 | 0.080 |
Why?
| Drainage | 1 | 2008 | 78 | 0.080 |
Why?
| Sulfonamides | 2 | 2008 | 129 | 0.080 |
Why?
| Myocardial Reperfusion | 1 | 2007 | 8 | 0.080 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2007 | 50 | 0.070 |
Why?
| Tetrazoles | 1 | 2007 | 41 | 0.070 |
Why?
| Dipyridamole | 1 | 2007 | 9 | 0.070 |
Why?
| Combined Modality Therapy | 1 | 2009 | 636 | 0.070 |
Why?
| Prosthesis Failure | 2 | 2012 | 107 | 0.070 |
Why?
| Microinjections | 2 | 2018 | 29 | 0.070 |
Why?
| Waiting Lists | 1 | 2007 | 50 | 0.070 |
Why?
| Prostaglandin D2 | 1 | 2007 | 21 | 0.070 |
Why?
| Cyclooxygenase 1 | 1 | 2007 | 5 | 0.070 |
Why?
| Sex Factors | 2 | 2022 | 693 | 0.070 |
Why?
| Thoracic Surgery | 1 | 2007 | 16 | 0.070 |
Why?
| Nitroso Compounds | 1 | 2006 | 4 | 0.070 |
Why?
| Patient Admission | 1 | 2007 | 77 | 0.070 |
Why?
| Analysis of Variance | 1 | 2008 | 565 | 0.070 |
Why?
| Calcium Signaling | 1 | 2007 | 56 | 0.070 |
Why?
| Enzyme Induction | 1 | 2006 | 80 | 0.070 |
Why?
| Cardiac Output, Low | 1 | 2006 | 7 | 0.070 |
Why?
| Biotin | 1 | 2006 | 45 | 0.070 |
Why?
| PPAR gamma | 1 | 2007 | 73 | 0.070 |
Why?
| Chest Pain | 1 | 2006 | 53 | 0.070 |
Why?
| Ubiquinone | 1 | 2006 | 12 | 0.070 |
Why?
| NF-kappa B | 1 | 2008 | 314 | 0.070 |
Why?
| Drug Interactions | 1 | 2007 | 206 | 0.070 |
Why?
| Acute Disease | 3 | 2019 | 369 | 0.070 |
Why?
| Hemofiltration | 1 | 2006 | 7 | 0.070 |
Why?
| Magnesium | 1 | 2006 | 35 | 0.070 |
Why?
| Heart Atria | 1 | 2006 | 55 | 0.070 |
Why?
| Electric Countershock | 1 | 2006 | 30 | 0.070 |
Why?
| Preoperative Care | 1 | 2007 | 167 | 0.070 |
Why?
| Intracranial Embolism | 1 | 2006 | 27 | 0.070 |
Why?
| Forecasting | 1 | 2007 | 150 | 0.070 |
Why?
| Diagnosis, Differential | 2 | 2012 | 1036 | 0.070 |
Why?
| Ischemic Preconditioning | 1 | 2005 | 4 | 0.070 |
Why?
| Texas | 2 | 2006 | 137 | 0.070 |
Why?
| Radiology | 1 | 2008 | 132 | 0.070 |
Why?
| Aortic Rupture | 1 | 2006 | 19 | 0.070 |
Why?
| Triiodobenzoic Acids | 1 | 2005 | 9 | 0.070 |
Why?
| Partnership Practice | 1 | 2005 | 1 | 0.070 |
Why?
| Myocardial Stunning | 1 | 2005 | 1 | 0.070 |
Why?
| Organizational Affiliation | 1 | 2005 | 2 | 0.070 |
Why?
| Health Planning | 1 | 2005 | 13 | 0.070 |
Why?
| Carbazoles | 1 | 2005 | 16 | 0.070 |
Why?
| Heart Transplantation | 1 | 2009 | 312 | 0.070 |
Why?
| Gastrointestinal Hemorrhage | 1 | 2006 | 78 | 0.070 |
Why?
| Metoprolol | 1 | 2005 | 13 | 0.070 |
Why?
| Foreign Bodies | 1 | 2006 | 65 | 0.060 |
Why?
| Device Removal | 1 | 2006 | 85 | 0.060 |
Why?
| Disease Progression | 1 | 2008 | 822 | 0.060 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 121 | 0.060 |
Why?
| Aortic Coarctation | 1 | 2006 | 31 | 0.060 |
Why?
| Accidents, Traffic | 1 | 2006 | 87 | 0.060 |
Why?
| Arginine Vasopressin | 1 | 2005 | 8 | 0.060 |
Why?
| Isoxazoles | 1 | 2005 | 14 | 0.060 |
Why?
| Intramolecular Oxidoreductases | 1 | 2005 | 14 | 0.060 |
Why?
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 26 | 0.060 |
Why?
| Education, Medical, Continuing | 1 | 2005 | 68 | 0.060 |
Why?
| Pyrrolidines | 1 | 2006 | 83 | 0.060 |
Why?
| Ephedrine | 1 | 2004 | 21 | 0.060 |
Why?
| Tetralogy of Fallot | 1 | 2006 | 86 | 0.060 |
Why?
| Regional Blood Flow | 1 | 2004 | 108 | 0.060 |
Why?
| Leadership | 1 | 2005 | 100 | 0.060 |
Why?
| Hyperhomocysteinemia | 1 | 2004 | 29 | 0.060 |
Why?
| Polyethylene Terephthalates | 1 | 2004 | 10 | 0.060 |
Why?
| Brachiocephalic Trunk | 1 | 2004 | 6 | 0.060 |
Why?
| Membrane Proteins | 1 | 2007 | 342 | 0.060 |
Why?
| Ventricular Remodeling | 1 | 2004 | 54 | 0.060 |
Why?
| Creatinine | 1 | 2004 | 140 | 0.060 |
Why?
| Pregnancy Complications, Cardiovascular | 1 | 2004 | 34 | 0.060 |
Why?
| Antioxidants | 1 | 2006 | 248 | 0.060 |
Why?
| Random Allocation | 1 | 2005 | 280 | 0.060 |
Why?
| Arteriosclerosis | 1 | 2004 | 54 | 0.060 |
Why?
| Swine Diseases | 1 | 2004 | 7 | 0.060 |
Why?
| Abnormalities, Multiple | 1 | 2006 | 167 | 0.060 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2005 | 201 | 0.060 |
Why?
| Inflammation | 2 | 2007 | 604 | 0.060 |
Why?
| Potassium Channels | 1 | 2004 | 31 | 0.060 |
Why?
| Enoxaparin | 1 | 2024 | 27 | 0.060 |
Why?
| ATP-Binding Cassette Transporters | 1 | 2004 | 34 | 0.060 |
Why?
| Hypertension | 2 | 2011 | 532 | 0.060 |
Why?
| Atrial Fibrillation | 1 | 2006 | 177 | 0.060 |
Why?
| Heart Diseases | 1 | 2006 | 208 | 0.060 |
Why?
| Cytochrome P-450 Enzyme System | 1 | 2005 | 195 | 0.060 |
Why?
| Glomerular Filtration Rate | 2 | 2018 | 111 | 0.060 |
Why?
| Vasoconstrictor Agents | 1 | 2004 | 84 | 0.060 |
Why?
| Creatine Kinase | 1 | 2003 | 29 | 0.060 |
Why?
| Sample Size | 1 | 2003 | 37 | 0.060 |
Why?
| Staphylococcus aureus | 1 | 2007 | 326 | 0.060 |
Why?
| Isoenzymes | 1 | 2003 | 168 | 0.050 |
Why?
| Retroperitoneal Space | 1 | 2002 | 30 | 0.050 |
Why?
| Death | 1 | 2022 | 20 | 0.050 |
Why?
| C-Reactive Protein | 1 | 2003 | 142 | 0.050 |
Why?
| Quality of Life | 1 | 2008 | 833 | 0.050 |
Why?
| Internship and Residency | 1 | 2008 | 446 | 0.050 |
Why?
| Cardiomyopathies | 1 | 2003 | 108 | 0.050 |
Why?
| Immunohistochemistry | 1 | 2005 | 971 | 0.050 |
Why?
| Drug Synergism | 3 | 2007 | 150 | 0.050 |
Why?
| Renal Dialysis | 1 | 2003 | 169 | 0.050 |
Why?
| Morphine Derivatives | 1 | 2022 | 29 | 0.050 |
Why?
| Anesthesia | 1 | 2002 | 73 | 0.050 |
Why?
| Mass Screening | 1 | 2004 | 351 | 0.050 |
Why?
| Hospitals | 1 | 2022 | 175 | 0.050 |
Why?
| Kidney | 1 | 2005 | 665 | 0.050 |
Why?
| Benchmarking | 2 | 2011 | 65 | 0.050 |
Why?
| Heart Arrest | 1 | 2002 | 148 | 0.050 |
Why?
| Tissue Scaffolds | 1 | 2020 | 32 | 0.050 |
Why?
| Arkansas | 2 | 2016 | 1967 | 0.050 |
Why?
| Biocompatible Materials | 1 | 2020 | 68 | 0.040 |
Why?
| Public Policy | 2 | 2012 | 38 | 0.040 |
Why?
| Oxidative Stress | 1 | 2004 | 768 | 0.040 |
Why?
| Anti-Inflammatory Agents | 2 | 2015 | 162 | 0.040 |
Why?
| Risk Adjustment | 1 | 2019 | 18 | 0.040 |
Why?
| Mice, Knockout | 2 | 2014 | 841 | 0.040 |
Why?
| Injections, Intralesional | 1 | 2018 | 31 | 0.040 |
Why?
| Internationality | 1 | 2018 | 36 | 0.040 |
Why?
| Radiation Dosage | 1 | 2019 | 157 | 0.040 |
Why?
| Administration, Intravenous | 1 | 2018 | 68 | 0.040 |
Why?
| Immunoblotting | 2 | 2008 | 118 | 0.040 |
Why?
| Radiation Monitoring | 1 | 2017 | 7 | 0.040 |
Why?
| International Cooperation | 2 | 2007 | 44 | 0.040 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 245 | 0.040 |
Why?
| Italy | 1 | 2015 | 26 | 0.030 |
Why?
| Mice | 3 | 2014 | 5720 | 0.030 |
Why?
| Blood Flow Velocity | 1 | 2015 | 99 | 0.030 |
Why?
| Phlebography | 1 | 2015 | 62 | 0.030 |
Why?
| Tubulin Modulators | 1 | 2015 | 31 | 0.030 |
Why?
| Cross-Sectional Studies | 1 | 2020 | 1541 | 0.030 |
Why?
| Cause of Death | 2 | 2007 | 145 | 0.030 |
Why?
| Syndrome | 2 | 2006 | 234 | 0.030 |
Why?
| Time | 1 | 2014 | 25 | 0.030 |
Why?
| Journal Impact Factor | 1 | 2014 | 8 | 0.030 |
Why?
| Models, Cardiovascular | 2 | 2004 | 21 | 0.030 |
Why?
| Genetic Vectors | 1 | 2014 | 127 | 0.030 |
Why?
| Fibrosis | 1 | 2014 | 178 | 0.030 |
Why?
| Monitoring, Physiologic | 1 | 2014 | 121 | 0.030 |
Why?
| Learning Curve | 1 | 2013 | 18 | 0.030 |
Why?
| Ischemic Attack, Transient | 1 | 2013 | 56 | 0.030 |
Why?
| Apoptosis | 2 | 2011 | 1100 | 0.030 |
Why?
| Cardiac Imaging Techniques | 1 | 2012 | 8 | 0.030 |
Why?
| Gene Expression Regulation | 2 | 2008 | 979 | 0.030 |
Why?
| Mice, Inbred C57BL | 2 | 2008 | 1806 | 0.030 |
Why?
| Tissue Survival | 1 | 2012 | 10 | 0.030 |
Why?
| Myocardial Perfusion Imaging | 1 | 2012 | 16 | 0.030 |
Why?
| Exercise Test | 2 | 2002 | 121 | 0.020 |
Why?
| Phosphodiesterase 3 Inhibitors | 1 | 2011 | 1 | 0.020 |
Why?
| Tomography, Emission-Computed, Single-Photon | 1 | 2012 | 52 | 0.020 |
Why?
| Adrenergic beta-1 Receptor Antagonists | 1 | 2011 | 6 | 0.020 |
Why?
| Health Policy | 1 | 2012 | 153 | 0.020 |
Why?
| In Situ Nick-End Labeling | 1 | 2011 | 57 | 0.020 |
Why?
| Echocardiography | 2 | 2005 | 378 | 0.020 |
Why?
| Recovery of Function | 1 | 2012 | 189 | 0.020 |
Why?
| Diagnostic Imaging | 1 | 2012 | 176 | 0.020 |
Why?
| Infusions, Intravenous | 1 | 2011 | 207 | 0.020 |
Why?
| Critical Care | 1 | 2012 | 201 | 0.020 |
Why?
| Program Development | 1 | 2011 | 166 | 0.020 |
Why?
| Data Collection | 1 | 2011 | 279 | 0.020 |
Why?
| Adrenergic beta-2 Receptor Antagonists | 1 | 2009 | 1 | 0.020 |
Why?
| Adrenergic beta-2 Receptor Agonists | 1 | 2009 | 2 | 0.020 |
Why?
| Transplantation, Homologous | 1 | 2009 | 138 | 0.020 |
Why?
| Graft Rejection | 1 | 2009 | 159 | 0.020 |
Why?
| Isoquinolines | 1 | 2008 | 25 | 0.020 |
Why?
| Cell Death | 1 | 2009 | 181 | 0.020 |
Why?
| Serine | 1 | 2008 | 38 | 0.020 |
Why?
| Tyrphostins | 1 | 2008 | 9 | 0.020 |
Why?
| Janus Kinases | 1 | 2008 | 8 | 0.020 |
Why?
| Selection Bias | 1 | 2008 | 15 | 0.020 |
Why?
| Electrophoretic Mobility Shift Assay | 1 | 2008 | 73 | 0.020 |
Why?
| Ischemic Preconditioning, Myocardial | 1 | 2007 | 2 | 0.020 |
Why?
| Organ Culture Techniques | 1 | 2007 | 50 | 0.020 |
Why?
| Creatine Kinase, BB Form | 1 | 2007 | 1 | 0.020 |
Why?
| Enzyme Activation | 1 | 2008 | 276 | 0.020 |
Why?
| Receptors, Purinergic P1 | 1 | 2007 | 8 | 0.020 |
Why?
| Survival | 1 | 2007 | 13 | 0.020 |
Why?
| Theophylline | 1 | 2007 | 19 | 0.020 |
Why?
| Immunologic Factors | 1 | 2008 | 114 | 0.020 |
Why?
| 5'-Nucleotidase | 1 | 2007 | 12 | 0.020 |
Why?
| Nitriles | 1 | 2007 | 54 | 0.020 |
Why?
| Blood Coagulation | 1 | 2007 | 57 | 0.020 |
Why?
| Butadienes | 1 | 2007 | 48 | 0.020 |
Why?
| Models, Chemical | 1 | 2007 | 66 | 0.020 |
Why?
| Premedication | 1 | 2007 | 21 | 0.020 |
Why?
| Smoking | 1 | 2011 | 510 | 0.020 |
Why?
| Drug Combinations | 1 | 2007 | 123 | 0.020 |
Why?
| Coenzymes | 1 | 2006 | 3 | 0.020 |
Why?
| Oncogene Protein v-akt | 1 | 2006 | 10 | 0.020 |
Why?
| Fluid Therapy | 1 | 2007 | 79 | 0.020 |
Why?
| Alanine | 1 | 2006 | 42 | 0.020 |
Why?
| Protein Kinase Inhibitors | 1 | 2008 | 202 | 0.020 |
Why?
| Phosphoric Monoester Hydrolases | 1 | 2006 | 22 | 0.020 |
Why?
| Receptors, Vasopressin | 1 | 2006 | 23 | 0.020 |
Why?
| Amidines | 1 | 2006 | 8 | 0.020 |
Why?
| Benzylamines | 1 | 2006 | 15 | 0.020 |
Why?
| Educational Measurement | 1 | 2008 | 210 | 0.020 |
Why?
| Sulfones | 1 | 2006 | 24 | 0.020 |
Why?
| PTEN Phosphohydrolase | 1 | 2006 | 55 | 0.020 |
Why?
| Research Design | 1 | 2008 | 343 | 0.020 |
Why?
| Models, Animal | 1 | 2006 | 233 | 0.020 |
Why?
| Magnetic Resonance Angiography | 1 | 2006 | 77 | 0.020 |
Why?
| Heart Conduction System | 1 | 2005 | 24 | 0.020 |
Why?
| Nitric Oxide | 1 | 2007 | 253 | 0.020 |
Why?
| Body Weight | 1 | 2007 | 513 | 0.020 |
Why?
| Safety | 1 | 2005 | 78 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 2007 | 391 | 0.020 |
Why?
| Multicenter Studies as Topic | 1 | 2005 | 84 | 0.020 |
Why?
| Nitroglycerin | 1 | 2004 | 7 | 0.020 |
Why?
| Radiography | 1 | 2006 | 489 | 0.020 |
Why?
| Injections, Intravenous | 1 | 2004 | 140 | 0.020 |
Why?
| Aortography | 1 | 2004 | 35 | 0.010 |
Why?
| Sensitivity and Specificity | 1 | 2006 | 854 | 0.010 |
Why?
| Glyburide | 1 | 2004 | 6 | 0.010 |
Why?
| Anastomosis, Surgical | 1 | 2004 | 68 | 0.010 |
Why?
| Ventricular Fibrillation | 1 | 2004 | 16 | 0.010 |
Why?
| Health Personnel | 1 | 2007 | 241 | 0.010 |
Why?
| Anesthesia, Obstetrical | 1 | 2004 | 39 | 0.010 |
Why?
| Models, Biological | 1 | 2007 | 728 | 0.010 |
Why?
| Statistics as Topic | 1 | 2004 | 89 | 0.010 |
Why?
| Vascular Surgical Procedures | 1 | 2006 | 168 | 0.010 |
Why?
| Patient Discharge | 1 | 2006 | 322 | 0.010 |
Why?
| Tachycardia, Ventricular | 1 | 2004 | 43 | 0.010 |
Why?
| Anti-Arrhythmia Agents | 1 | 2004 | 79 | 0.010 |
Why?
| Transcription Factors | 1 | 2007 | 563 | 0.010 |
Why?
| NG-Nitroarginine Methyl Ester | 1 | 2003 | 18 | 0.010 |
Why?
| Cesarean Section | 1 | 2004 | 187 | 0.010 |
Why?
| Swine | 1 | 2004 | 391 | 0.010 |
Why?
| Endpoint Determination | 1 | 2002 | 24 | 0.010 |
Why?
| Brain | 1 | 2006 | 1309 | 0.010 |
Why?
| Pregnancy | 1 | 2004 | 2584 | 0.010 |
Why?
|
|
Uretsky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|